Israel's currency is strong because its economy is strong and the strong shekel rewards efficiency and benefits consumers.
Teva was not the right match for Pfizer, probably because Mylan's financial ratios were much better.
Revenue from the natural gas fields will not make a major difference in Israel's budget in the coming years, but it can be used to reduce budget deficits.
With falling revenue, a huge debt and nothing in its arsenal, the Israeli company can only make even more cuts.
With a huge long-term debt, Teva's biggest problem is the lack of revenue growth engines to replace Copaxone.
Teva has no growth engine to compensate for Copaxone and the fall in US generics prices.
The Israeli pharmaceutical company's aggressive streamlining plan is bearing fruit but the fundamental problems remain.
The banks' move on Eurocom is meant to cover up for their sins, but there is a public interest that takes precedence over theirs.
Teva's reliance on Copaxone made the company complacent, obese, and excessively self-confident.
The government is criticizing the high prices charged by toiletries importers while the industry profit margins leader is local manufacturer Sano.
Some Israeli media headlines depicted Kite as an Israeli exit. But it is a US company that does no business in Israel and has no employees here.